Search Result

Results for "

dry eye.

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Biochemical Assay Reagents (2) CFTR (1) Collagen (1) Endogenous Metabolite (1) Glucocorticoid Receptor (2) Integrin (4) Isotope-Labeled Compounds (3) JAK (2) Mucin (1) NF-κB (1) P2Y Receptor (2) Reactive Oxygen Species (1) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (1) TNF Receptor (1) TRP Channel (2)
By Research Areas:	Endocrinology (1) Inflammation/Immunology (20) Neurological Disease (4)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	siRNAs (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B2206

Gefarnate	Mucin	Inflammation/Immunology
Gefarnate is a agent used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome.

HY-B1893

Fluorometholone 1 Publications Verification	Glucocorticoid Receptor	Inflammation/Immunology
Fluorometholone, a synthetic glucocorticoid, is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic properties. Fluorometholone can be used for the research of dry eye .

HY-B0606

Diquafosol tetrasodium 5 Publications Verification INS365	P2Y Receptor	Inflammation/Immunology
Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.

HY-132596A

Tivanisiran sodium SYL1001 sodium	TRP Channel	Neurological Disease
Tivanisiran sodium is a siRNA used for the study of dry eye disease. Tivanisiran sodium was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA .

HY-169675

Lacripep	Endogenous Metabolite	Neurological Disease Endocrinology
Lacripep is a synthetic tear protein. Lacripep binds to and activates syndecan-1 (SDC1). Lacripep restores progenitor cell identity and epithelial barrier function. Lacripep resolves dry eye .

HY-P10904

Vezocolmitide	Collagen	Others
Vezocolmitide is a collagen mimetic peptide and is the component of ST-100. Vezocolmitide can be used for research of dry eye disease (DED) .

HY-152264

CFTR activator 1	CFTR	Inflammation/Immunology
CFTR activator 1 is a potent and selective CFTR activator, with an EC₅₀ of 23 nM. CFTR activator 1 can be used to ameliorate dry eye disease .

HY-132596

Tivanisiran SYL1001	Small Interfering RNA (siRNA) TRP Channel	Neurological Disease
Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) .

HY-151611

UAMC-00050	Ser/Thr Protease	Inflammation/Immunology
UAMC-00050 is a potent trypsin-like serine protease inhibitor. UAMC-00050 can be used in research of dry eye syndrome and ocular inflammation .

HY-P99578

Tanfanercept HL036337; HBM9036	TNF Receptor	Inflammation/Immunology
Tanfanercept (HL036337) is an TNF-α receptor fusion protein that targets TNF-α. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model .

HY-B0606A

Diquafosol INS365 free base	Apoptosis P2Y Receptor Reactive Oxygen Species	Inflammation/Immunology
Diquafosol (INS365 free base) is a potent P2Y2 agonist. Diquafosol nhibits apoptosis and decreases ROS generation. Diquafosol has the potential for the research of dry eye .

HY-B1893R

Fluorometholone (Standard) 1 Publications Verification	Glucocorticoid Receptor	Inflammation/Immunology
Fluorometholone (Standard) is the analytical standard of Fluorometholone. This product is intended for research and analytical applications. Fluorometholone, a synthetic glucocorticoid, is a glucocorticoid receptor agonist with anti-inflammatory and anti-allergic properties. Fluorometholone can be used for the research of dry eye .

HY-107150

Reproxalap ADX-102; NS-2	NF-κB	Neurological Disease Inflammation/Immunology
Reproxalap (ADX-102) is an active aldehyde sequestering agent that's being researched for dry eye syndrome, allergic conjunctivitis, and non-infectious anterior uveitis. Reproxalap has anti-inflammatory and pain-relieving effects .

HY-153565

Immune cell migration-IN-1	Others	Inflammation/Immunology
Immune cell migration-IN-1 (compound 2) is a potent agent to inhibit immune cell migration. Immune cell migration-IN-1 can be used for research in alleviating dry eye diseases, eczema dermatitis and psoriasis .

HY-154994

JAK-IN-30	JAK	Inflammation/Immunology
JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC₅₀ values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) .

HY-U00277

JAK-IN-10	JAK	Inflammation/Immunology
JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders . JAK-IN-10 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19344

Lifitegrast 5 Publications Verification SAR 1118; SHP-606	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344A

Lifitegrast sodium 5 Publications Verification SAR 1118 sodium; SHP-606 sodium	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .

HY-19344S2

Lifitegrast-d4-1	Isotope-Labeled Compounds Integrin	Inflammation/Immunology
Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-153567

Immune cell migration-IN-2	Biochemical Assay Reagents	Inflammation/Immunology
Immune cell migration-IN-2 is a potent immune cell migration inhibitor with an EC₅₀ of 13.5 nM in a T-cell adhesion assay. Immune cell migration-IN-2 is extracted from patent WO2019001171, example 11, can be used for dry-eye and other retinal diseases research . Immune cell migration-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19344R

Lifitegrast (Standard)	Integrin	Inflammation/Immunology
Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4 SAR 1118-d₄; SHP-606-d₄	Isotope-Labeled Compounds	Inflammation/Immunology
Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S1

Lifitegrast-d6 SAR 1118-d₆; SHP-606-d₆	Isotope-Labeled Compounds	Inflammation/Immunology
Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-17639

Navamepent RX-10045	Biochemical Assay Reagents	Inflammation/Immunology
Navamepent is an analog of naturally occurring resolvin E1 (a major dietary omega-3 polyunsaturated fatty-acid metabolite) with potent anti-inflammatory and cell survival benefits. Navamepent is highly effective against dry eye and goblet cell loss thereby accelerating tear production. Also, Navamepent can reduce corneal inflammation, epithelial damage, and accelerate corneal tissue repair. In addition, Navamepent can inhibit the release of several key proinflammatory mediators from corneal epithelial cells. Navamepent is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Target	Research Area

HY-169675

Lacripep	Endogenous Metabolite	Neurological Disease Endocrinology
Lacripep is a synthetic tear protein. Lacripep binds to and activates syndecan-1 (SDC1). Lacripep restores progenitor cell identity and epithelial barrier function. Lacripep resolves dry eye .

HY-P10904

Vezocolmitide	Collagen	Others
Vezocolmitide is a collagen mimetic peptide and is the component of ST-100. Vezocolmitide can be used for research of dry eye disease (DED) .

Cat. No.	Product Name	Target	Research Area

HY-P99578

Tanfanercept HL036337; HBM9036	TNF Receptor	Inflammation/Immunology
Tanfanercept (HL036337) is an TNF-α receptor fusion protein that targets TNF-α. Tanfanercept is effective in ameliorating corneal erosions in a dry eye (DE) mouse model .

Cat. No.	Product Name	Chemical Structure

HY-19344S2

Lifitegrast-d4-1
Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d4-1

Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4
Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d4

Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S1

Lifitegrast-d6
Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d6

Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Cat. No.	Product Name		Classification

HY-U00277

JAK-IN-10		Alkynes
JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders . JAK-IN-10 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-17639

Navamepent RX-10045		Alkynes
Navamepent is an analog of naturally occurring resolvin E1 (a major dietary omega-3 polyunsaturated fatty-acid metabolite) with potent anti-inflammatory and cell survival benefits. Navamepent is highly effective against dry eye and goblet cell loss thereby accelerating tear production. Also, Navamepent can reduce corneal inflammation, epithelial damage, and accelerate corneal tissue repair. In addition, Navamepent can inhibit the release of several key proinflammatory mediators from corneal epithelial cells. Navamepent is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-132596A

Tivanisiran sodium SYL1001 sodium		siRNAs
Tivanisiran sodium is a siRNA used for the study of dry eye disease. Tivanisiran sodium was designed to silence transient receptor potential vanilloid 1 (TRPV1) mRNA .

HY-132596

Tivanisiran SYL1001		siRNAs
Tivanisiran (SYL1001) is a siRNA used for the study of dry eye disease. Tivanisiran was designed to silence transient receptor potential vanilloid 1 (TRPV1) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: